Evidence map›Paper›PMID 36010206›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Comparison of a Blood Self-Collection System with Routine Phlebotomy for SARS-CoV-2 Antibody Testing.

Douglas Wixted, Coralei E Neighbors, Carl F Pieper, Angie Wu, Carla Kingsbury, Heidi Register, Elizabeth Petzold, L Kristin Newby, Christopher W Woods

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Decentralized Clinical Trials in Early Drug Development-A Framework Proposal.Journal of immunotherapy and precision oncology · 2024
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Douglas WixtedDuke Clinical and Translational Science Institute, Duke University, Durham, NC 27701, USA.ORCID 0000-0002-6128-7813
Coralei E NeighborsDuke Global Health Institute, Duke University, Durham, NC 27710, USA.ORCID 0000-0002-0367-2983
Carl F PieperDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA.
Angie WuDepartment of Clinical Research, Cytel Inc., Waltham, MA 02451, USA.
Carla KingsburyDuke Clinical and Translational Science Institute, Duke University, Durham, NC 27701, USA.
Heidi RegisterDuke Human Vaccine Institute, Duke University, Durham, NC 27710, USA.
Elizabeth PetzoldCenter for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, NC 27708, USA.
L Kristin NewbyDuke Clinical and Translational Science Institute, Duke University, Durham, NC 27701, USA.ORCID 0000-0002-6394-8187
Christopher W WoodsDepartments of Medicine and Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Duke University · USDuke Medical Center · US

Funding

Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI Sarah B. Peskoe · 2006 to 2026
$24.6M
Duke Claude D. Pepper Older Americans Independence Center Grant 5P30AG028716-15NCATS NIH HHS UL1 TR002553NCATS NIH HHS UL1TR002553NC Department of Health and Human Services 00042568NIA NIH HHS P30 AG028716
6 · The paper itself

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic forced researchers to reconsider in-person assessments due to transmission risk. We conducted a pilot study to evaluate the feasibility of using the Tasso-SST (Tasso, Inc, Seattle, Washington) device for blood self-collection for use in SARS-CoV-2 antibody testing in an ongoing COVID-19 prevalence and immunity research study. 100 participants were recruited between January and March 2021 from a previously identified sub-cohort of the Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study who were under-going bimonthly COVID-19 antibody testing. Participants were given a Tasso-SST kit and asked to self-collect blood during a scheduled visit where trained laboratory personnel performed routine phlebotomy. All participants completed an after-visit survey about their experience. Overall, 70.0% of participants were able to collect an adequate sample for testing using the device. Among those with an adequate sample, there was a high concordance in results between the Tasso-SST and phlebotomy blood collection methods (Cohen’s kappa coefficient = 0.88, Interclass correlation coefficient 0.98 [0.97, 0.99], p < 0.0001). The device received a high-level (90.0%) of acceptance among all participants. Overall, the Tasso-SST could prove to be a valuable tool for seroprevalence testing. However, future studies in larger, diverse populations over longer periods may provide a better understanding of device usability and acceptance among older participants and those with comorbidities in various use scenarios.

Indexed as

antibody testingcapillary bloodcoronavirusCOVID-19infectious diseaseSARS-CoV-2self-collectionTasso-SSTuser acceptance

Identifiers

PMID36010206
PMCPMC9406345
OpenAlexW4289109289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.